SoFi stock falls after announcing $1.5B public offering of common stock
NATICK, Mass. - Allurion Technologies, Inc. (NYSE:ALUR) reported Tuesday that patients using its Smart Capsule balloon in combination with low-dose tirzepatide achieved an average 23% total body weight loss after 12 months, while increasing lean body mass by 14%. The company’s shares, currently trading at $1.13, have fallen 89% year-to-date and sit just 4 cents above their 52-week low, according to InvestingPro data.
The initial results come from 76 patients who received the Allurion Smart Capsule and began low-dose tirzepatide therapy (2.5mg, later increased to no more than 5.0mg) after their first 45 days of balloon therapy. This dosage is significantly lower than standard tirzepatide treatment, which can reach 15mg.
All patients remained on tirzepatide for the full eight-month medication period and were monitored for an additional two months after discontinuation using Allurion’s AI-powered Virtual Care Suite.
The company highlighted that the combination approach addresses two significant challenges associated with GLP-1 medications: muscle wasting and adherence issues. Previous studies have shown that GLP-1 therapy alone can reduce lean mass by approximately 40% of total weight lost, with 58% of patients discontinuing before reaching meaningful health benefits.
"By combining these two therapies that have distinct physiological mechanisms of action and following patients closely using AI-powered virtual care, we can unlock increased weight loss while still increasing lean mass," said Dr. Luigi Flagiello from Clinica Ruesch, who oversaw the case series.
Dr. Shantanu Gaur, Founder and CEO of Allurion, indicated the company plans to validate these results in a prospective clinical trial. The Allurion Smart Capsule remains an investigational device in the United States.
The company stated that additional data from this case series is being collected and is expected to be presented at upcoming medical meetings, according to the press release.
In other recent news, Allurion Technologies Inc. reported a significant decline in its Q3 2025 revenue, which fell to $2.7 million from $5.4 million during the same period last year. Despite the revenue drop, the company managed to reduce its operating loss by 22%, bringing it down to $9.6 million. In a strategic move to expand its weight loss program in Brazil, Allurion announced a partnership with ProSurg Medical, leveraging ProSurg’s extensive network and experience in the Brazilian market. Additionally, a new study published in Obesity Surgery highlighted the effectiveness of the Allurion Smart Capsule, showing a 20% average weight reduction in patients over 36 weeks. This result is comparable to outcomes seen with bariatric surgery and high-dose GLP-1 therapy. These developments reflect Allurion’s ongoing efforts to adapt to market shifts and explore new growth opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.